Among those who were no longer eligible, some subjects were deceased (2); there was reported progression of disease (2) and an increase in serum PSA (22); other treatments were initiated (radiation, hormone therapy) (15); some moved out of State (9); and some were diagnosed with another cancer other than prostate (1). Here, KLK3 is linked to male reproductive organ cancer.